Skip to Content

Join the 'Namzaric' group to help and get support from people like you.

Namzaric News

Study: Gene Test Needed Before Using Alzheimer's Drug 'Off-Label'

Posted 8 Mar 2017 by Drugs.com

TUESDAY, March 7, 2017 – A drug used to treat Alzheimer's disease should not be prescribed to people with milder mental impairment without first giving them a genetic test, a new study urges. The drug is donepezil (brand name: Aricept). Donepezil could speed mental decline in someone with mild cognitive impairment who has a specific genetic variation, according to Sophie Sokolow, an associate professor at the UCLA School of Nursing. She and her colleagues found that patients with the K-variant of the butyrylcholinesterase (BChE) gene who took donepezil deteriorated faster than those who took a placebo. Donepezil is approved in the United States to treat Alzheimer's disease but not mild cognitive impairment – the stage between normal age-related decline and dementia. However, doctors often prescribe it "off-label" for patients with mild cognitive impairment, the study authors said. For ... Read more

Related support groups: Dementia, Alzheimer's Disease, Aricept, Donepezil, Mild Cognitive Impairment, Namzaric, Aricept ODT, Donepezil/memantine, Dementia with Depressive Features, Head Imaging

Dementia Meds May Lead to Harmful Weight Loss: Study

Posted 3 Aug 2015 by Drugs.com

MONDAY, Aug. 3, 2015 – A class of drugs widely used to treat dementia – called cholinesterase inhibitors – could cause harmful weight loss in some patients, a new study suggests. These medications include Aricept (donepezil), Razadyne (galantamine) and Exelon (rivastigmine). "Our study provides evidence in a large, real-world population that cholinesterase inhibitors may contribute to clinically significant weight loss in a substantial proportion of older adults with dementia," study lead author Dr. Meera Sheffrin, a geriatrics fellow in the School of Medicine, at the University of California, San Francisco, said in a university news release. One expert said the findings point out a common problem for Alzheimer's patients. "Weight loss is a concern, not only for patients but also for their overwhelmed caregivers, who keep struggling with multiple challenges, including providing their ... Read more

Related support groups: Weight Loss, Dementia, Alzheimer's Disease, Aricept, Donepezil, Exelon, Mild Cognitive Impairment, Rivastigmine, Arteriosclerotic Dementia, Galantamine, Cachexia, Reminyl, Razadyne, Razadyne ER, Tacrine, Cognex, Namzaric, Lewy Body Dementia, Aricept ODT, Donepezil/memantine

Ask a Question

Further Information

Related Condition Support Groups

Alzheimer's Disease

Namzaric Patient Information at Drugs.com